If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
== External links == Zeiss Official Page Comparison of early visual outcomes after low-energy SMILE, high-energy SMILE and LASIK for myopia and myopic astigmatism in the United States Frequently Asked Questions About Small Incision Lenticule Extraction (SMILE) | Official Zeiss Publication
==== Other adverse effects ==== High doses of nicotinic acid can also cause niacin maculopathy, a thickening of the macula and retina, which leads to blurred vision and blindness. This maculopathy is reversible after niacin intake ceases. Niaspan, the slow-release product, has been associated with a reduction in platelet content and a modest increase in prothrombin time.
CT is the total inorganic carbon [CO2*] is the sum of carbon dioxide and carbonic acid concentrations ([CO2*] = [CO2] + [H2CO3]) [HCO−3] is the bicarbonate concentration [CO2−3] is the carbonate concentration Each of these species are related by the following pH-driven chemical equilibria:
Sources: en.wikipedia.org
HVEC's entry into high-energy research accelerators began in 1949 with its 4 MV Cosmotron particle injector. By 1951, HVEC had begun producing its single-ended CN series that became the first mass-produced research accelerators. The CN design was based on a vertical accelerator at MIT designed by John Trump. It employed resistor grading in both column and tube structure, field-shaping column hoops, and high-pressure insulating gas mixtures of nitrogen and carbon dioxide. Operating in a single stage at terminal voltages up to 6.5 megavolts, the 26 CN models manufactured by HVEC reliable platforms for light-ion nuclear physics experiments. However, fundamental physics questions, particularly the structure of heavier nuclei, demanded higher particle energies than a single-stage Van de Graaff accelerator could reach.
Doxylamine acts primarily as an antagonist or inverse agonist of the histamine H1 receptor. This action is responsible for its antihistamine and sedative properties. To a lesser extent, doxylamine acts as an antagonist of the muscarinic acetylcholine receptors, an action responsible for its anticholinergic and (at high doses) deliriant effects.
== Bibliography == Move That Mountain (1976), ISBN 978-0-88270-164-6 Eight Keys to Success (1980), ISBN 978-0-89221-071-8 I Was Wrong (1996), ISBN 978-0-7852-7425-4 Prosperity and the Coming Apocalypse (1998), ISBN 978-1-4185-5422-4 The Refuge: The Joy of Christian Community in a Torn-Apart World (2000), ISBN 978-1-4185-5423-1 Time Has Come: How to Prepare Now for Epic Events Ahead (2014), ISBN 978-1-61795-134-3 You Can Make It: God's Faithfulness in Dark Times-Past, Present and Future (2021) ISBN 978-1-63641-047-0
A recent droplet-PCR PDMS device allowed for higher accuracy and amplification of small copy numbers in comparison to traditional quantitative PCR experiments. This higher accuracy was due to surfactant-doped PDMS as well as a sandwiched glass-PDMS-glass device design. These device properties have allowed for more streamlined priming of DNA and less water evaporation during PCR cycling.
Sources: en.wikipedia.org
=== Age-related differences === While the amino acid scores for PDCAAS and DIAAS are based on toddler requirements (1–3 year olds), the essential amino acid requirements differ for adults and infants. The most demanding essential amino acid requirements are for infants; when children become adults, they need lower proportions of essential amino acids. This also means that many of the vegan protein sources that are limited in one or more essential amino acids, are actually less deficient in essential amino acids for adults, perhaps not deficient at all. Old age and pregnancy also change amino acid requirements, because of the necessity of supporting a fetus or slowing the loss of muscle due to age. The essential amino acid requirements for infants are based on the essential amino acid proportions in human breast milk.
== Continuum Assumption == The continuum assumption is an idealization of continuum mechanics under which fluids can be treated as continuous, even though, on a microscopic scale, they are composed of molecules. Under the continuum assumption, macroscopic (observed/measurable) properties such as density, pressure, temperature, and bulk velocity are taken to be well-defined at "infinitesimal" volume elements—small in comparison to the characteristic length scale of the system, but large in comparison to molecular length scale. Fluid properties can vary continuously from one volume element to another and are average values of the molecular properties. The continuum hypothesis can lead to inaccurate results in applications like supersonic speed flows, or molecular flows on nano scale. Those problems for which the continuum hypothesis fails can be solved using statistical mechanics or rarefied gas dynamics. To determine whether or not the continuum hypothesis applies, the Knudsen number, defined as the ratio of the molecular mean free path to the characteristic length scale, is evaluated. Problems with Knudsen numbers below 0.1 can be evaluated using the continuum hypothesis, but molecular approach (statistical mechanics) can be applied to find the fluid motion for larger Knudsen numbers.
=== Self-healing materials === For materials such as components in microelectronics, polymeric coatings, and adhesives, nanocapsules can reduce damage caused by high loads. The healing of cracks within these materials is alleviated by dispersing nanocapsules within the polymer. The healing substances include dicyclopentadiene (DCPD), which is prepared on site within the material by sonication. The nanoencapsulated material is first emulsified within the host material by creating an oil-in-water self-healing epoxy. The emulsified material is then agitated within the host material to form particles which then bond to the host material.
Kombucha can be prepared at home or commercially. It is made by dissolving sugar in non-chlorinated boiling water. Tea leaves are then steeped in the hot sugar water and discarded. The sweetened tea is cooled and the SCOBY culture is added. The mixture is then poured into a sterilized beaker along with previously fermented kombucha tea to lower the pH. This technique is known as "backslopping". The container is covered with a paper towel or breathable fabric to prevent insects, such as fruit flies, from contaminating the kombucha. The tea is left to ferment for a period of up to 10 to 14 days at room temperature, 18–26 °C (64–79 °F). A new "daughter" SCOBY will form on the surface of the tea to the diameter of the container. After fermentation is completed, the SCOBY is removed and stored along with a small amount of the newly fermented tea. The remaining kombucha is strained and bottled for a secondary ferment for a few days or stored at 4 °C (39 °F).
Soybeans were a crucial crop in East Asia long before written records began. The origin of soy cultivation remains scientifically debated. The closest living relative of the soybean is Glycine soja (previously called G. ussuriensis), a legume native to central China. Genomic data increasingly supports a single domestication event in north-central China between 6,000 and 9,000 years ago, although some evidence suggests a more complex scenario involving low-intensity pre-domestication cultivation across multiple locations in East Asia, followed by the eventual dominance of the Chinese lineage. There is evidence for soybean domestication between 7000 and 6600 BC in China, between 5000 and 3000 BC in Japan and 1000 BC in Korea. The first unambiguously domesticated, cultigen-sized soybean was discovered in Korea at the Mumun-period Daundong site. Prior to fermented products such as fermented black soybeans (douchi), jiang (Chinese miso), soy sauce, tempeh, nattō, and miso, soy was considered sacred for its beneficial effects in crop rotation, and it was eaten by itself, and as bean curd and soy milk. Soybeans were introduced to Java in Malay Archipelago circa 13th century or probably earlier. By the 17th century, through their trade with the Far East, soybeans and their products were traded by European traders (Portuguese, Spanish, and Dutch) in Asia and reached the Indian Subcontinent by this period. By the 18th century, soybeans were introduced to the Americas and Europe from China.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.